Oncology Drug Payment Reconciliation: Finding True Underpayments

How do you identify a true oncology drug underpayment?

Compare the adjudicated drug line with a documented expected allowance derived from the correct service-date methodology, product, units, and applicable payment terms. A low deposit is not automatically an underpayment. The difference may reflect patient responsibility, contractual adjustments, coordination of benefits, payment reductions, a quantity issue, or an actual pricing error. CMS publishes quarterly Medicare Part B drug payment-limit files, but those files do not establish every payer's contractual allowance or guarantee coverage. Review the remittance and claim together before disputing payment. This workflow deliberately avoids quoting unverified 2026 drug amounts or assuming a universal reimbursement formula.

Build the expected-payment record

Record the payer product, billing setting, service date, drug code, supported units, submitted modifiers, and pricing source. For Medicare review, identify the applicable quarterly file and any revision affecting that period. For a commercial contract, locate the actual drug payment provision and relevant amendments rather than substituting a familiar Medicare benchmark. Document whether the comparison concerns the allowed amount or the payer's net remittance, because those are different figures. Keep acquisition cost analysis separate: a payment below purchasing cost may raise a business concern without proving the payer violated its payment methodology.

Hypothetical scenario: a quantity discrepancy, not a rate dispute

A fictional drug claim reports 20 supported HCPCS units. The remittance reflects payment for 10 units, while the practice's worksheet initially labels the difference a pricing underpayment. The reviewer checks the transmitted claim, payer response, and administration record, then determines whether the quantity changed during submission or adjudication. If the payer priced only half the supported units, the dispute should focus on quantity and the applicable correction process rather than alleging that the per-unit rate was wrong. If the original claim itself contained 10 units, correct the claim appropriately. The example uses no real drug rate or promised recovery.

Reconcile the entire adjudication

Read claim adjustment and remittance information before calculating a demand. Separate allowed amount, payer payment, deductible, coinsurance, contractual adjustments, and other relevant offsets. Confirm whether a secondary payer is expected to respond and whether a later reversal or replacement remittance changed the original result. For discarded-drug lines, verify that the underlying quantity and modifier were supported before treating nonpayment as a pricing error. Avoid adding the same variance from multiple remittance versions to the recovery queue. A clear audit trail should show the original adjudication, subsequent changes, and the remaining amount actually in dispute.

Use a payment-variance checklist

Prioritize exceptions using practice-defined operational criteria, not invented regulatory thresholds. A useful worksheet explains the calculation well enough for another reviewer to reproduce it and includes the exact policy or contract language supporting the expected amount. If the reference is uncertain, label the variance unresolved rather than declaring an underpayment. Aggregate recurring patterns by product, payer, and cause after validating individual examples. This helps distinguish a systematic configuration issue from an isolated claim error and keeps unsupported demands out of the appeal process.

• Validate product, HCPCS descriptor, modifiers, and supported units.
• Select the correct service-date pricing or contractual reference.
• Compare allowed amount separately from net payer payment.
• Account for reversals, patient responsibility, and other adjustments.
• Document the variance cause and appropriate dispute pathway.

Respect payer and payment-system differences

Medicare physician-office drug payment, hospital outpatient payment, Medicare Advantage arrangements, and commercial contracts can use different rules. Do not apply a Part B payment-limit file as though it resolves every facility or negotiated payment question. CMS also notes that a code's inclusion or omission in the payment file does not determine coverage. If the drug lacks a published limit, investigate the applicable contractor or payer process instead of inventing an amount. Verify whether the payer's issue is coverage, coding, quantity, or price, because each may require a different response and supporting evidence.

Allocate combined remittances before measuring drug recovery

A payer deposit may cover several encounters while its remittance includes claim payments and provider-level adjustments. Reconcile the deposit to the full remittance before assigning a cash shortfall to a particular drug line. Keep any unresolved provider-level adjustment in a separate reconciliation category with its reference and investigation owner. If an adjustment later proves related to a specific claim, link the supporting notice before reallocating it. This prevents a correct drug allowance from being labeled underpaid merely because an unrelated recoupment reduced the same deposit, and keeps subsequent recovery calculations tied to the actual disputed line.

Close the loop between posting and recovery

Assign validated variances to an owner, record the filing requirements, and retain proof of every submission. Post any additional payment against the original disputed line and explain residual balances rather than closing the account merely because the payer responded. Feed recurring quantity or pricing errors back into charge capture and payment configuration. Cyber Sense can support payment posting and oncology billing workflows that connect expected allowances to remittance review. Request a consultation to discuss variance categorization, source maintenance, and follow-up ownership. Reconciliation can identify supported disputes; it cannot guarantee additional payment or turn an unfavorable but correct contract term into an underpayment.

Frequently asked questions

Related articles

• Oncology Infusion Time Documentation: Building a Defensible Start–Stop Record
• Oncology Drug HCPCS Unit Reconciliation: From Administered Dose to Claim
• JW and JZ in Oncology: Confirming Discarded-Drug Reporting Scope